New Epilepsy Drugs Work by Jamming Brain Receptor
Details from study in rat brain cells could lead to more effective antiepileptic drugs with fewer side effects
Columbia University Medical Center (CUMC) researchers have discovered how a new epilepsy drug works, which may lead the way to even more effective and safer medications. The most commonly used anti-epilepsy drugs are ineffective for about 30 percent of people with seizure disorders. A new direction in the treatment of epilepsy is aimed at inhibiting AMPA receptors, which help transmit electrical signals in the brain and play a key role in propagating seizures. Currently, perampeanel is the only FDA-approved drug that targets AMPA receptors. But because perampanel is associated with significant side effects, its clinical use has been limited. To read more, click here.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2017
Oct. 26-28, 2017; Jacksonville, Fla.
Pituitary Tumors: Diagnostic and Treatment Dilemmas
Oct. 27, 2017; New York
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
8th World Congress of Neuroendoscopy
Nov. 1-4, 2017; Cape Town, South Africa
3rd Annual Selected Topics in Craniomaxillofacial Surgery
Nov. 4, 2017 - Nov. 5, 2017; Boston, Mass.